Mark V. Larson, M.D.

Closed for Enrollment

• A Randomized, Double-Blind, Placebo-Controlled, Phase IIa Proof-of-Concept Study of GIC-1001 for the Management of Visceral Pain in Subjects Undergoing Sedation-Free, Full Colonoscopy Rochester, Minn., Scottsdale/Phoenix, Ariz.

  The purpose of this study is to assess the effectiveness and safety of GIC-1001, a new, orally-administered, colon analgesic drug, developed to manage visceral pain, as an alternative to sedation during a full colonoscopy.